YOU ARE HERE > Home > Bookstore > The French Pharma Market - 2023 prospects >

The French Pharma Market - 2023 prospects

Description

 “The French Pharma Market – 2018-2023 prospects” report provides a description of the French healthcare system from a legal, organizational and economic point of view.  

This new edition offers in a clear, precise and concise format:

 

Product details

Soft copy: 300 pages (PowerPoint)
Language: English
Price: €6,000 (excl. tax)

Consult short version

 

  

Contents

Introduction

·         Foreword

·         International healthcare expenditure

·         Global pharma market (2018 – 2023)

 

Section 1. The French healthcare system

1.1. Key stakeholders

·         Mapping of key stakeholders

·         Policy makers and regulators

·         Overall reimbursement and pricing processes

·         Parliament and Ministry of Health

·         ANSM

·         HAS (CEESP – CT) 

·         CEPS

·         National and regional market access in a nutshell

·         Market access – European comparisons

·         Social Security and Complementary Health Insurance Systems

·         National Health Insurance Fund instances

·         Compulsory complementary health insurance plan

·         Complementary health cover organizations

·         National, regional and local organization of the Social Health Insurance System

·         Regional health agencies

·         Healthcare professionals and facilities

·         Hospital funding systems

·         Drug distribution channels

·         Economy of retail pharmacies

·         Voluntary trade organizations

·         On-line sales of pharmaceutical products

·         Patients confidence in drugs

 

1.2. Recent reforms 

·         The French Sunshine Act

·         LFSS 2014: New regulations towards generics and biosimilars

·         LFSS 2015 key articles regarding drugs and pharma companies

·         LFSS 2016 key articles regarding drugs and pharma companies

·         Health System Modernization Act (incl. GHT)

·         LFSS 2017 key articles regarding drugs and pharma companies

·         LFSS 2018 key articles regarding drugs and pharma companies

·         "My Health 2022": Territorial reorganization of care project

·         LFSS 2018 main saving measures

·         LFSS 2019 main saving measures

·         LFSS 2019 key articles regarding drugs and pharma companies

·         The future of GAFA / Telemedicine

 

1.3. Healthcare expenditure 

·         Relation between healthcare expenditure and GDP

·         Supply, consumption and funding of healthcare

·         Breakdown of healthcare expenditure and coverage

·         Social Security & national health insurance fund balances

·         ONDAM

·         Hospital expenses

·         Expenditure by age group

·         Evolution of the reimbursement system

·         Price cuts and economic impact

·         Main governmental measures relative to generics and biosimilars

·         Drivers and limiters of the OTC market


Section 2. The French pharmaceutical market

2.1. Evolution of drugs sales

·         Classification of pharmaceutical products in France

·         Evolution of drugs sales by segment (2013 – 2018)

·         Hospital market dynamics (2013 – 2018)

·         Evolution of drugs sales by reimbursement rate (2013 – 2018)

·         Top 10 therapeutic areas retail & hospital (2018)

·         Top 10 products retail & hospital (2018)

·         Generics penetration – International comparisons (2017)

·         Generics penetration (1999 – 2018)

·         Evolution of reimbursable generics in the retail market 

·         Molecules having lost their patent protection in 2018

·         Savings generated by generics (2013 – 2018)

·         Evolution of the biosimilar market (2007 – 2018)

·         OTC market size and structure (2018)

·         Top 10 therapeutic areas in the OTC market (2018)

·         Top 10 brands and umbrella brands in the OTC market (2018)

·         Sales of drugs on top of T2A (2013 – 2018)

 

2.2. Evolution of pharma companies sales

·         Top 10 pharma companies retail and hospital market (2018)

·         Top 10 pharma companies on the retail market (2018)

·         Top 10 pharma companies on the hospital market (2018)

·         Top 10 generics companies on the retail market (2018)

·         Top 10 pharma companies on the biosimilars market (2018)

·         Top 10 pharma companies on the OTC market (2018)

·         Top 10 generics companies on the hospital market (2018)

 

2.3. Future market trends

·         Factors driving the evolution of drugs sales by market segment (2019 – 2023)

·         Drugs sales forecast by segment (2019 – 2023)

 

Section 3. Strategic priorities for pharma companies

3.1. Introduction (7 Ps)

 

3.2. Policy makers and Payers

·         2019-2023 trends

·         Driving factors

·         Implications

·         Strategic priorities

 

3.3. Physicians

·         2019-2023 trends

·         Driving factors

·         Implications

·         Strategic priorities

 

3.4. Pharmacists

·         2019-2023 trends

·         Driving factors

·         Implications

·         Strategic priorities

 

3.5. Patients & PAGs

·         2019-2023 trends

·         Driving factors

·         Implications

·         Strategic priorities

 

3.6. Pharma competitors

·         2019-2023 trends

·         Driving factors

·         Implications

·         Strategic priorities 


Executive Summary

 

Glossary